|
See related Survanta intratracheal susp information |
|
|
|
Manufacturer |
Abbott |
|
Distributor |
Hong Kong: Zuellig/Macau: The Glory Medicina |
|
Contents |
Beractant (equiv to phospholipids 25 mg/mL, triglyceride 0.5-1.75 mg/mL, free fatty acids 1.4-3.5 mg/mL, proteins <1 mg/mL) |
|
Indications |
Prevention & treatment ("rescue") of resp distress syndrome (RDS) (hyaline membrane disease) in premature infant.
Click to view Survanta detailed prescribing infomation |
|
Dosage |
100 mg phospholipids/kg body wt (4 mL/kg).
Click to view Survanta detailed prescribing infomation |
|
Special Precautions |
click to view Survanta detailed prescribing infomation |
|
Adverse Drug Reactions |
Transient bradycardia, O2 desaturation, endotracheal tube reflux, pallor, vasoconstriction, hypotension, endotracheal tube blockage, HTN, hypocarbia, hypercarbia, apnoea.
View ADR Monitoring Form |
|
Description |
View Survanta description for details of the chemical structure and excipients (inactive components). |
|
Mechanism of Action |
View Survanta mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
Presentation/Packing |
|
Form |
Packing |
Photo |
|
Survanta intratracheal suspension |
|
Survanta (vial) 25 mg/1 mL x 8 mL x 1's |
 |
|
|
|
Manufacturer: |
Abbott |
|
Distributor: |
Hong Kong: Zuellig
Macau: The Glory Medicina |
|
|
|
